HCG and Fertility on TRT: How to Preserve Your Options

You started TRT because you felt terrible. Low energy, no libido, brain fog. Now the testosterone is doing its job, you feel like yourself again, and your partner brings up having kids. Or maybe you're 25, running your first blast, and fatherhood is a vague "someday" plan you haven't thought through yet.

Either way, you need to understand what exogenous testosterone does to your sperm, what you can do about it, and which blood tests actually tell you whether your fertility is intact.

How TRT shuts down fertility

Your reproductive system runs on a feedback loop called the HPG axis (hypothalamic-pituitary-gonadal). The hypothalamus releases GnRH in pulses, which tells the pituitary to secrete LH and FSH. LH drives the Leydig cells in your testes to produce testosterone. FSH drives the Sertoli cells to support spermatogenesis.

When you inject exogenous testosterone, your brain detects the elevated serum levels and shuts down GnRH output. No GnRH means no LH, no FSH. Your Leydig cells go dormant, your Sertoli cells lose their FSH signal, and sperm production collapses.

Here is the number that makes this concrete: intratesticular testosterone (ITT) in healthy men runs roughly 100 times higher than serum testosterone. Serum T of 14 nmol/L coexists with ITT of 1,174 nmol/L inside the testes (Coviello et al., 2005). On TRT without HCG, ITT drops by up to 94%. Your blood work might show a perfect testosterone level, but your testes are running on fumes.

The timeline is faster than most men expect. In the WHO male contraceptive trials, 65% of men on 200 mg/week testosterone enanthate reached azoospermia (zero sperm) within 6 months, with the average man hitting zero by about 120 days (WHO, 1990). At supraphysiological bodybuilding doses, complete suppression can occur within 6 to 10 weeks.

19-nors make it worse

Nandrolone and trenbolone activate progesterone receptors in addition to androgen receptors. This dual-receptor suppression hits GnRH output harder than testosterone alone and persists long after the compound clears your system. Nandrolone also causes direct testicular damage: seminiferous tubule shortening, reduced testicular volume, and germ cell death beyond what testosterone produces (Desai et al., 2022).

If you have used 19-nor compounds for extended periods, your recovery timeline will be materially longer than someone who ran testosterone only.

Does TRT make you infertile permanently?

Usually not, but it depends on how long you have been on and how old you are.

The best recovery data comes from a pooled analysis of 1,549 men across 30 hormonal contraception studies: after stopping testosterone, 67% recovered to 20 million sperm/mL by 6 months, 90% by 12 months, and 96% by 16 months (Liu et al., 2006). However, up to 10% of men remain azoospermic at 12 months without medical intervention (McBride & Coward, 2016).

With HCG-based therapy, recovery is significantly faster. In 49 men with TRT-induced azoospermia treated with HCG 3,000 IU every other day plus a SERM, spermatogenesis returned in 95.9% of cases, with an average first sperm density of 22.6 million/mL at a mean of 4.6 months (Wenker et al., 2015).

The two strongest predictors of recovery time are age and duration of testosterone use. In 66 men treated with HCG plus SERMs, both older age and longer prior TRT duration independently delayed sperm recovery at 6 and 12 months (Kohn et al., 2017). A 40-year-old who used TRT for 8 years faces a fundamentally different outlook than a 25-year-old finishing his first 16-week cycle.

HCG for fertility preservation: how it works

HCG (human chorionic gonadotropin) is a glycoprotein hormone that mimics LH at the Leydig cell receptor. It bypasses the suppressed pituitary entirely and tells your Leydig cells to keep producing intratesticular testosterone. This is the mechanism by which HCG prevents testicular atrophy and preserves at least partial spermatogenesis during TRT.

The landmark dose-response study established the dosing window. Coviello et al. (2005) put 29 men on 200 mg/week testosterone enanthate, then co-administered HCG at varying doses:

• 125 IU every other day: ITT was 25% below baseline (insufficient)
• 250 IU every other day: ITT was only 7% below baseline (effectively normal)
• 500 IU every other day: ITT was 26% above baseline (supra-normal)

This is why clinicians use 250 to 500 IU every other day, not arbitrary numbers. The evidence defines the effective range.

In a separate study of 26 hypogonadal men on TRT with concomitant HCG 500 IU every other day, zero patients became azoospermic and 9 out of 26 (34.6%) contributed to a pregnancy (Hsieh et al., 2013).

What HCG cannot do

HCG is an LH analogue. It stimulates Leydig cells to produce testosterone. It has no meaningful activity at the FSH receptor on Sertoli cells. FSH is what drives spermatogenesis at the cellular level: it tells Sertoli cells to nurture developing sperm through their 74-day maturation cycle.

HCG alone can maintain enough intratesticular testosterone to prevent complete azoospermia, but it cannot replace the FSH signalling required for quantitatively normal sperm production. This distinction matters. Many men believe HCG is a complete fertility solution. It is not. It is a damage-limitation tool that keeps the machinery from shutting down entirely.

LH receptor desensitisation

Chronic high-dose HCG causes LH receptor downregulation on Leydig cells. A single large dose can reduce LH binding sites to less than 10% of baseline within hours, suppressing both cAMP accumulation (~70% reduction) and testosterone output (~55% reduction) for approximately 3 days (Smals et al., 1984).

This is why the old bodybuilding protocol of blasting 5,000 IU HCG twice a week is pharmacologically self-defeating. High, infrequent doses desensitise the very receptors you are trying to stimulate. Lower, more frequent doses (250-500 IU every other day) maintain receptor sensitivity while delivering adequate ITT support.

Choosing your protocol by fertility urgency

The right approach depends on when you want to conceive. Here is the evidence-based framework:

For men actively trying to conceive, stopping TRT and combining HCG with a SERM is the most effective approach. The SERM restores pituitary FSH secretion (which HCG cannot do), while HCG maintains intratesticular testosterone from the Leydig cell side. This dual-pathway stimulation produced the 95.9% recovery rate in the Wenker study.

When HCG alone is not enough

If semen parameters have not improved after 3 to 6 months of HCG plus a SERM, the evidence supports adding recombinant FSH (rFSH) at 75 IU every other day. A 2024 study treating 77 men with HCG 3,000 IU plus FSH 75 IU three times weekly found that 74% demonstrated improved sperm concentrations, and concurrent testosterone therapy did not impede recovery (Stocks et al., 2025). The correct escalation step is adding FSH, not increasing the HCG dose.

Enclomiphene, gonadorelin, and other alternatives

The 2020 HCG access problem

In March 2020, the FDA reclassified HCG from a small-molecule drug to a biologic product. Compounding pharmacies, which do not hold biologics licenses, lost the ability to produce compounded HCG. Supply contracted, prices rose, and clinicians began looking for alternatives. This regulatory shift, not new clinical evidence, is the primary reason enclomiphene and gonadorelin entered mainstream TRT practice.

Enclomiphene: the cleaner SERM

Enclomiphene is the isolated trans-isomer of clomiphene. Standard clomiphene (Clomid) is a 60:40 mix of enclomiphene and zuclomiphene. The problem is zuclomiphene: it accumulates over weeks of use due to its much longer half-life compared to enclomiphene, and acts as an estrogen agonist. This causes the mood disturbances, libido suppression, and visual changes that give Clomid its reputation.

Enclomiphene avoids this entirely. It blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback and driving the pituitary to increase both LH and FSH. In a randomised trial, enclomiphene maintained sperm concentrations of 75 to 334 million/mL at 3 and 6 months, while men on testosterone gel failed to maintain sperm counts above 20 million/mL (Kaminetsky et al., 2013). A 2024 comparative study confirmed enclomiphene produced significantly fewer side effects than clomiphene, including lower estradiol elevation (-5.92 vs. +17.50 pg/mL, P = 0.001) (Saffati et al., 2024).

Gonadorelin: upstream GnRH stimulation

Gonadorelin is a synthetic decapeptide identical to your body's own GnRH. It acts at the top of the HPG axis, stimulating the pituitary to release both LH and FSH in physiological pulses. In theory, this preserves the most natural HPTA signalling cascade of any option.

In a trial of men with hypogonadotropic hypogonadism, pulsatile gonadorelin achieved spermatogenesis significantly earlier than conventional HCG/HMG therapy (median 6 months vs. 14 months) (Zhang et al., 2019). Gonadorelin also avoids the E2 spikes associated with HCG and does not desensitise Leydig cell LH receptors.

The practical downside: gonadorelin has a half-life measured in minutes, requiring subcutaneous injections twice daily. Most compounding pharmacy protocols suggest 100 to 200 mcg twice daily, but this has not been validated in large RCTs specifically in TRT patients.

HCG vs enclomiphene vs gonadorelin

For the bodybuilding population: enclomiphene offers the most practical profile (once-daily oral, stimulates both LH and FSH, minimal side effects). HCG remains the most evidence-backed option for direct ITT preservation. Gonadorelin is the most physiologically elegant but least convenient. No head-to-head RCT has compared all three in men on exogenous testosterone.

Does HCG raise estrogen on TRT?

Yes, and this is one of the most common practical problems when adding HCG to an existing TRT protocol.

HCG stimulates Leydig cell aromatase directly. In healthy men given a single 1,500 IU HCG injection, estradiol peaked at 4.4 times baseline at 24 hours, while testosterone only peaked at 2.1 times baseline at 48 hours (Smals et al., 1984). The E2 rise is disproportionate to the testosterone rise because HCG upregulates the aromatase enzyme before the full steroidogenic cascade peaks.

If you are already well-controlled on TRT with, say, 1 mg anastrozole per week, expect your E2 to climb when you add HCG. Recheck estradiol at 6 to 8 weeks after adding or adjusting your HCG dose.

But here is the nuance that matters for fertility: some estradiol is required for spermatogenesis. Male aromatase knockout mice develop progressive infertility with spermatogenesis arrested at early spermiogenic stages (Robertson et al., 1999). Estradiol modulates fluid reabsorption in the efferent ductules and directly influences late spermatid maturation (Schulster et al., 2016).

Aggressive AI use during a fertility protocol is counterproductive. The goal is to keep E2 in a physiological range (roughly 20 to 55 pg/mL), not to crush it to the floor. If you are experiencing genuine high-E2 symptoms (puffy nipples, excessive water retention, emotional instability), adjust your AI dose. If your E2 is elevated but you feel fine, leave it alone. For a deeper dive on E2 management, see our estradiol on TRT guide.

The fertility bloodwork panel

Most TRT bloodwork panels are not designed to assess fertility. Here is what you actually need and what each marker tells you.

Tier 1: every visit

Draw total testosterone and free testosterone at every visit. These are your baseline and response markers. On HCG therapy, rising T confirms Leydig cells are responding.

Estradiol (E2) tracks the aromatisation burden from HCG. Recheck 6 to 8 weeks after any dose change.

FSH tells you what the pituitary is doing. On TRT alone, FSH will be near zero. On a SERM like enclomiphene, rising FSH confirms the drug is working. On HCG alone, FSH stays suppressed because HCG does not stimulate pituitary FSH release.

Tier 2: when spermatogenesis is the specific concern

Inhibin B is produced by Sertoli cells in proportion to the number of functional spermatogonia. In 1,797 fertile men, inhibin B below 150 pg/mL strongly correlated with low sperm counts (Jorgensen et al., 2010). Inhibin B declines before FSH rises in early testicular failure, making it a more direct and sensitive index of spermatogenesis. It tells you what the testes are doing; FSH tells you what the pituitary thinks.

SHBG independently predicts decreased sperm concentration and motility (Ring et al., 2017), adding fertility-predictive information beyond total testosterone.

Prolactin: hyperprolactinaemia suppresses GnRH pulsatility and can mimic AAS-induced hypogonadism. Check once at baseline, especially if LH and FSH are unexpectedly low. Particularly relevant if you have used 19-nor compounds, which elevate prolactin independently.

Progesterone is suppressed on AAS as part of HPTA shutdown. Recovery of progesterone is a useful marker of overall HPTA restoration during PCT.

Tier 3: semen analysis

A semen analysis is the only objective measure of whether you can conceive. Blood tests tell you about hormone levels and signalling. A semen analysis tells you about actual sperm.

WHO 2021 lower reference limits (5th centile from 3,589 fertile men): sperm concentration 16 million/mL, total motility 42%, progressive motility 30%, normal morphology 4% (Campbell et al., 2021). These are lower reference limits, not targets.

When to test:

Motility and morphology often recover before total count normalises. A semen analysis showing low count but improving motility is a positive sign.

A note about LH on HCG

Do not panic when your LH comes back suppressed or undetectable while on HCG. This is expected. HCG stimulates the testes directly, and the resulting testosterone and estradiol suppress pituitary LH through normal negative feedback. Suppressed LH on HCG therapy means the drug is working, not that your HPTA is broken. The correct question is not "is my LH normal?" but "is spermatogenesis occurring?". The answers come from inhibin B and semen analysis, not LH.

How long does sperm recovery take after TRT?

This depends on three variables: whether you use medical intervention, how long you were on testosterone, and whether you used 19-nor compounds.

Spontaneous recovery without medical intervention follows the Liu pooled data well: 67% reach 20 million/mL by 6 months, 90% by 12 months, 96% by 16 months, with a median time to personal baseline of 6.7 months (Liu et al., 2006).

HCG-accelerated recovery looks considerably better. Mean time to spermatogenesis is 4.6 months, with a 95.9% success rate using HCG plus a SERM (Wenker et al., 2015). 70% achieve a total motile count above 5 million within 12 months (Kohn et al., 2017).

Men who have used nandrolone or trenbolone for extended periods face a different situation entirely. Recovery timelines of 12 to 24+ months are realistic. The progesterone receptor-mediated suppression persists independently of androgen clearance, and the direct testicular toxicity from these compounds means there may be less functional tissue to recover. If you have been on a nandrolone-containing blast-and-cruise protocol for years, plan for a longer road and discuss rFSH add-on therapy with your specialist early.

Practical recommendations

1. If kids are even a remote possibility, freeze sperm before starting TRT or AAS. Period.
2. If you are already on TRT and want to preserve the option, add HCG 250-500 IU every other day to your protocol. This is the minimum effective approach for testicular maintenance.
3. If you are actively trying to conceive, stop TRT, start HCG 3,000 IU EOD plus enclomiphene 12.5-25 mg/day, and get a semen analysis at 3 months. If you have been on TRT for less than 2 years and are under 35, your odds are excellent.
4. If 3-6 months of HCG plus a SERM fails, do not increase the HCG dose. Add rFSH 75 IU every other day. This is the evidence-supported escalation.
5. Monitor the right markers: FSH (pituitary response), inhibin B (testicular spermatogenesis), estradiol (aromatisation burden), and semen analysis (the actual answer). Forget about LH while on HCG.
6. Do not crush your estradiol during a fertility protocol. Spermatogenesis needs E2. Aim for symptom-based management, not a number.

For a complete guide on when to draw your bloodwork relative to your TRT injections, see our blood test timing guide. If you are coming off testosterone entirely and running PCT, our PCT bloodwork article covers the full recovery monitoring protocol.

Key takeaways

• TRT suppresses FSH and LH, dropping intratesticular testosterone by up to 94% and causing azoospermia in most men within 4 to 6 months.
• HCG 250-500 IU every other day maintains ITT and prevents complete azoospermia, but does not replace FSH signalling for full spermatogenesis.
• Recovery rates with HCG-based therapy are 95.9% when combined with a SERM. Without treatment, roughly 10% of men remain azoospermic at 12 months.
• Age and duration of use are the strongest predictors of recovery time. Start early if you plan to conceive.
• Enclomiphene is the most practical alternative to HCG (oral, stimulates both LH and FSH, fewer side effects). Gonadorelin is physiologically elegant but requires twice-daily injections.
• Monitor FSH, inhibin B, estradiol, and semen analysis. LH is uninformative while on HCG.
• Do not suppress estradiol aggressively during fertility protocols. Spermatogenesis requires E2.
• When in doubt, freeze sperm before starting.

---

References

1. World Health Organization Task Force on Methods for the Regulation of Male Fertility. (1990). Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet, 336(8721), 955-959. PubMed

2. Coviello, A. D., Matsumoto, A. M., Bremner, W. J., Herbst, K. L., Amory, J. K., Anawalt, B. D., Sutton, P. R., Wright, W. W., Brown, T. R., Yan, X., Zirkin, B. R., & Jarow, J. P. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. Journal of Clinical Endocrinology and Metabolism, 90(5), 2595-2602. PubMed

3. Hsieh, T. C., Pastuszak, A. W., Hwang, K., & Lipshultz, L. I. (2013). Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. Journal of Urology, 189(2), 647-650. PubMed

4. Wenker, E. P., Dupree, J. M., Langille, G. M., Kovac, J., Ramasamy, R., Lamb, D., Mills, J. N., & Lipshultz, L. I. (2015). The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. Journal of Sexual Medicine, 12(6), 1334-1337. PubMed

5. Liu, P. Y., Swerdloff, R. S., Christenson, P. D., Handelsman, D. J., & Wang, C. (2006). Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet, 367(9520), 1412-1420. PubMed

6. McBride, J. A., & Coward, R. M. (2016). Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology, 18(3), 373-380. PubMed

7. Kohn, T. P., Louis, M. R., Pickett, S. M., Lindgren, M. C., Kohn, J. R., Pastuszak, A. W., & Lipshultz, L. I. (2017). Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertility and Sterility, 107(2), 351-357. PubMed

8. Kaminetsky, J., Werner, M., Fontenot, G., & Wiehle, R. D. (2013). Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. Journal of Sexual Medicine, 10(6), 1628-1635. PubMed

9. Saffati, G., Kassab, J., Orozco Rendon, D., Hinojosa-Gonzalez, D. E., Kronstedt, S., Lipshultz, L. I., & Khera, M. (2024). Enclomiphene versus clomiphene for male hypogonadism: a retrospective comparative study. Translational Andrology and Urology, 13(9), 1984-1990. PubMed

10. Zhang, L., Cai, K., Wang, Y., Ji, W., Cheng, Z., Chen, G., & Liao, Z. (2019). Pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. American Journal of Men's Health, 13(5), 1557988319876891. PMC

11. Smals, A. G., Pieters, G. F., Boers, G. H., Raemakers, J. M., Hermus, A. R., Benraad, T. J., & Kloppenborg, P. W. (1984). Differential effect of single high dose and divided small dose administration of human chorionic gonadotropin on Leydig cell steroidogenic desensitization. Journal of Clinical Endocrinology and Metabolism, 58(2), 327-331. PubMed

12. Jorgensen, N., Liu, F., Andersson, A. M., Vierula, M., Irvine, D. S., Auger, J., Brazil, C. K., Drobnis, E. Z., Jensen, T. K., Jouannet, P., Overstreet, J. W., Redmon, J. B., Sparks, A., Toppari, J., Wang, C., Skakkebaek, N. E., & Swan, S. H. (2010). Serum inhibin-b in fertile men is strongly correlated with low but not high sperm counts: a coordinated study of 1,797 European and US men. Fertility and Sterility, 94(6), 2128-2134. PubMed

13. Kumanov, P., Nandipati, K., Tomova, A., & Agarwal, A. (2006). Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertility and Sterility, 86(2), 332-338. PubMed

14. Schulster, M., Bernie, A. M., & Ramasamy, R. (2016). The role of estradiol in male reproductive function. Asian Journal of Andrology, 18(3), 435-440. PubMed

15. Robertson, K. M., O'Donnell, L., Jones, M. E., Meachem, S. J., Boon, W. C., Fisher, C. R., Graves, K. H., McLachlan, R. I., & Simpson, E. R. (1999). Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Proceedings of the National Academy of Sciences USA, 96(14), 7986-7991. PubMed

16. Campbell, M. J., Lotti, F., Baldi, E., Schlatt, S., Festin, M. P. R., Bjorndahl, L., Toskin, I., & Barratt, C. L. R. (2021). Distribution of semen examination results 2020: a follow-up of data collated for the WHO semen analysis manual 2010. Andrology, 9(3), 817-822. PubMed

17. Ring, J., Welliver, C., Parenteau, M., Markwell, S., Brannigan, R. E., & Kohler, T. S. (2017). The utility of sex hormone-binding globulin in hypogonadism and infertile males. Journal of Urology, 197(5), 1326-1331. PubMed

18. Stocks, B. T., Oppenheimer, A. G., Campbell, K. J., Lindsey, J. P., Kohn, T. P., Alexander, J. M., Huang, J. B., & Lipshultz, L. I. (2025). Optimal restoration of spermatogenesis after testosterone therapy using human chorionic gonadotropin and follicle-stimulating hormone. Fertility and Sterility, 123(4), 607-615. PubMed

19. Desai, A., Yassin, M., Cayetano, A., Tharakan, T., Jayasena, C. N., & Minhas, S. (2022). Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology, 14, 17562872221105017. PubMed